AlphaStocks
3.4
Weak

ARGENX SE (ARGX)

Health Care

ADR

$743.73

Scores poorly across most models. Proceed with caution.

Weak

Score based on 3 of 5 models — moderate confidence

#959out of 1127 in Health Care

Is ARGENX SE a Good Investment in 2026?

ARGENX SE (ARGX) scores 3.4 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating ARGENX SE as Neutral. However, the Graham model rates it Caution — Significantly above fair value. ARGENX SE currently trades above its estimated fair value of $543, suggesting limited upside at current prices. ARGENX SE ranks #959 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E35.3ROE19.3Market Cap46B

Estimated Fair Value

$542.9937% above

Trading above estimated fair value. P/e of 35x implies high growth expectations. rapid eps growth (51%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is ARGENX SE (ARGX) a good investment?
Based on AlphaStocks' composite analysis, ARGENX SE (ARGX) scores 3.4 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 35x implies high growth expectations. rapid eps growth (51%) partially justifies the premium.
What is ARGENX SE's Piotroski F-Score?
ARGENX SE's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ARGX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $543, ARGX appears overvalued. The stock currently trades 37% above its estimated fair value. Trading above estimated fair value. P/e of 35x implies high growth expectations. rapid eps growth (51%) partially justifies the premium.
How does ARGX compare to other Health Care stocks?
ARGENX SE ranks #959 out of 1127 stocks in the Health Care sector, placing it in the top 85% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ARGX?
AlphaStocks evaluates ARGX using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 3.4/10.

Similar Stocks

PARRFTIAZN

Compare ARGX with

ARGX vs PARRARGX vs FTIARGX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer